drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Allogeneic, gene-engineered CAR T-cell therapy targeting BCMA (TNFRSF17) and CD19 to deplete B-lineage cells and plasma cells, intended to reduce AQP4-IgG in refractory AQP4-IgG+ NMOSD; dosed at 1.0–4.0 x 10^6 CD3+CAR+ cells/kg.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic gene-engineered CAR T cells co-targeting BCMA (TNFRSF17) and CD19; upon antigen engagement they mediate cytotoxic killing of CD19+ B cells and BCMA+ plasmablasts/plasma cells, broadly depleting B-lineage cells and reducing pathogenic AQP4-IgG.
drug_name
BRL-302 (Universal BCMA-CD19 CAR-T cells)
nct_id_drug_ref
NCT06633042